SCIENCE SLAM: THE ROLE OF MRNA IN ENABLING A NEW GENERATION OF IMMUNO-ONCOLOGY PRODUCTS

mRNA has recently been demonstrated as a flexible aid for immuno-oncology ranging from a tool in the cell therapy workflow to targeted cancer therapies. The panel will address various challenges, opportunities and promise of mRNA use in immuno-oncology treatments.
Chair:
Scott Ripley, Ph.D., General Manager, Nucleic Acid Therapeutics and Precision Nanosystems, Cytiva
Speakers:
Adrian Bot, M.D., Ph.D., Chief Scientific Officer, Capstan Therapeutics
Andy Geall, Ph.D., Co-founder and Chief Development Officer, Replicate Biosciences
Sadik Kassim, Ph.D., Chief Technology Officer, Genomic Medicines, Danaher Corporation